title: Cancer disease predictive diagnosis: BAT/CD3-positive lymphocytes in cancer patients.
abstract: BAT is an immune-activating monoclonal antibody produced against Daudi cell membranes and selected for stimulating lymphocyte proliferation. The anti-tumor activity of BAT is related to its immunostimulatory properties. Both T and NK cells mediate the anti-tumor activity of BAT. CD4-positive T cells respond to BAT activation by proliferation and INF-gamma production. The aim of the study was to assess the probability that the BAT monoclonal antibody binding capacity to T cells is a marker for different cancers. Human peripheral blood T cells from colon, breast and prostate cancer patients, as well as healthy volunteer donors, were tested for the percentage of binding to BAT mAb (BAT/CD3 cells) by FACS analysis. All patients were tested before undergoing surgery or treatment, and their diagnosis was confirmed by histology. The results showed that the percentage of BAT monoclonal antibody binding to CD3-positive T cells in the peripheral blood was different in cancer patients with diverse tumor types. We found that lymphocytes from the blood of healthy donors contained 25% BAT/CD3 cells. In colon and breast cancer patients, a significant decrease to 13 and 11% of BAT/CD3 cells was found. In contrast, these cells increased ><50% in patients with prostate cancer. These findings may have a potential diagnostic significance and also assist in the evaluation of strategies for the therapeutic use of BAT for different cancer patients.
authors.affiliation: Felsenstein Medical Research Center, Rabin Medical Center-Beilinson Campus, Petah Tikva 49100, Israel. bhardy@post.tau.ac.il
authors.forename: Britta
authors.initials: B
authors.lastname: Hardy
authors.forename: Annat
authors.initials: A
authors.lastname: Raiter
authors.forename: Moshe
authors.initials: M
authors.lastname: Rubin
authors.forename: Elliot
authors.initials: E
authors.lastname: Sprecher
authors.forename: Avishai
authors.initials: A
authors.lastname: Sella
authors.forename: Dov
authors.initials: D
authors.lastname: Flex
authors.forename: Shlomo
authors.initials: S
authors.lastname: Lelcuk
authors.forename: Bassam
authors.initials: B
authors.lastname: Bsharah
authors.forename: Moshe
authors.initials: M
authors.lastname: Mishaeli
authors.forename: Yaron
authors.initials: Y
authors.lastname: Niv
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology*; D001943:Breast Neoplasms / Q000276:immunology* / Q000473:pathology*; D017252:CD3 Complex / Q000276:immunology*; D016022:Case-Control Studies; D002462:Cell Membrane; D049109:Cell Proliferation; D003110:Colonic Neoplasms / Q000276:immunology* / Q000473:pathology*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D051379:Mice; D016513:Mice, SCID; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000276:immunology* / Q000473:pathology*; D013601:T-Lymphocytes / Q000276:immunology*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D017252:CD3 Complex